Taiho Pharmaceutical Co., Ltd. (HQ: Tokyo, President and Representative Director: Masayuki Kobayashi) announced on August 29 that the company has entered into an agreement to invest up to US$30 million in Remiges Biopharma Fund II, LP a biopharma venture capital fund formed by Remiges Ventures, Inc. Taiho Pharmaceutical invested the same amount in the Remiges BioPharma Fund I established in 2014.
{iframe}https://www.prnewswire.com/news-releases/taiho-pharmaceutical-invests-in-new-venture-capital-fund-300908895.html{/iframe}